IMAC Holdings Reports Significant Financial Losses and Strategic Shift in Latest Quarterly Filing

IMAC Holdings, Inc. reported significant financial challenges in its latest quarterly filing for the period ending September 30, 2025. The company generated net revenues of $21,223 for the three months and $22,723 for the nine months, marking a substantial decline from $56,300 and $72,050, respectively, in the same periods of the previous year. The gross profit for the three months ended September 30, 2025, was a loss of $102,654, compared to a loss of $65,777 in the prior year. The net loss for the quarter was $3,078,533, which included a one-time impairment loss of $748,101 related to property and equipment.

The financial performance reflects a notable deterioration compared to the previous fiscal period. Total operating expenses surged to $2,498,945 for the three months ended September 30, 2025, up from $1,930,314 in the same quarter of 2024. This increase was primarily driven by higher salaries and benefits, as well as the impairment loss. For the nine-month period, operating expenses rose to $6,455,944 from $3,684,636, indicating a significant escalation in costs associated with the company's operations.

Strategically, IMAC Holdings has shifted its focus towards precision medicine in cancer treatment, following the acquisition of laboratory capabilities from Theralink Technologies, Inc. This acquisition is intended to enhance the company's offerings in oncology clinical treatment decisions. However, the company has also discontinued its previous operations related to patient care, which has been reflected in its financial statements as discontinued operations. The transition has resulted in a working capital deficit of $13 million as of September 30, 2025, compared to a deficit of $6.5 million at the end of 2024.

Operationally, the company reported a significant increase in current liabilities, which totaled approximately $13.3 million, driven by a rise in accounts payable and notes payable. The accumulated deficit reached $72.4 million, raising concerns about the company's ability to continue as a going concern. Management has indicated that it will need to raise additional capital to fund operations, with estimated capital needs of approximately $5 million over the next 12 months. The company is also facing challenges in attracting skilled personnel and managing overhead costs effectively.

Looking ahead, IMAC Holdings anticipates that its future success will depend on its ability to secure financing and effectively manage its operational costs. The company has expressed substantial doubt regarding its ability to continue as a going concern without additional funding. The management team is actively exploring options to raise capital, but there are no guarantees that these efforts will be successful, which could further impact the company's financial stability and operational capabilities.